FDA Inspection 1190349 — Pharmaplast S.A.E.

Pharmaplast S.A.E. — FEI 3003767891

The FDA completed an inspection of Pharmaplast S.A.E. on November 10, 2022 in Alexandria. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
November 10, 2022
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Alexandria (Egypt)

Citations

IDCFRDescription
113321 CFR 211.25(a)GMP Training Frequency
121521 CFR 211.67(b)Written procedures not established/followed
188321 CFR 211.165(a)Testing and release for distribution
201221 CFR 211.188(b)Batch production and Batch Control Record Requirements
201921 CFR 211.188(b)(7)Documentation of Actual Yield and Theoretical Yield
355221 CFR 211.48(a)Potable water not under positive pressure
356721 CFR 211.84(d)(2)Component identification test